Biomarker Analysis and Updated Results From the Phase Iii Propel Trial of Abiraterone (abi) and Olaparib (ola) Vs Abi and Placebo (pbo) as First-Line (1l) Therapy for Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcrpc)
Loading...
Files
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Open Access Color
OpenAIRE Downloads
OpenAIRE Views
Abstract
[Abstract Not Available]
Description
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- SEP 09-13, 2022 -- ELECTR NETWORK
Keywords
Fields of Science
Citation
WoS Q
Q1
Scopus Q
Q1
Source
Annals of Oncology
Volume
33
Issue
7
Start Page
S1160
End Page
S1160
Web of Science™ Citations
10
checked on Mar 06, 2026
Page Views
2
checked on Mar 06, 2026
